foralumab — Interim data
2026
Interim data are anticipated in 2026, with results intended to guide future development and potentially establish neuroimmune modulation as a key pillar in AD therapy.Source filing
TLSA biotech catalysts & pipeline
TIZIANA LIFE SCIENCES LTD · Data as of 2026-10-25
Upcoming catalysts
foralumab — Topline data
October
Tiziana expects to lock the database this week, and announce 12-week treatment topline data in October.Source filing
foralumab — Topline data
Q1 2027
Topline data are anticipated to be announced in Q1 2027.Source filing